MedWatch

Former Zealand chief ready for phase III studies in new company

He managed Zealand Pharma until 2015 and now David Solomon has taken the reins in a US-based biotech company preparing for pivotal phase III studies of its key asset next year. When the drug enters the market it will compete with one of the world’s most expensive therapies.

From September 2008 to January 2015, David Solomon was CEO of Zealand Pharma where he was responsible for taking the company public in 2011 as the latest life science company to list on the Copenhagen Stock Exchange.

Since then, he has been in a Norwegian biotech company and founded the life science investment fund Sund Capital. A little more than a month ago he took the reins in a US-based biotech company. Here, he hopes and believes that he can replicate the success he experienced during his six years in Zealand Pharma.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Tvivl om finansiering bag forskningsfradrag

Regeringen vil finansiere en forhøjelse af forsknings- og udviklingsfradraget med en sanering af erhvervsstøtteordningerne, men det lader sig ikke nødvendigvis gøre, lyder det fra Erhvervsstyrelsens tidligere direktør og De Konservatives finansordfører Rasmus Jarlov.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier